Altimmune (ALT) Stock Analysis & AI Equity Report
Altimmune (ALT) overview
Altimmune (ALT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 0.0m and operating profit of USD -94.5m; the year-end share price was 3.61 USD and market capitalisation was USD 400m. Altimmune is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Altimmune's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company developing pemvidutide, an investigational balanced glucagon/GLP-1 dual-receptor agonist. The candidate is being studied for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder and alcohol-associated liver disease. Its pipeline includes a global Phase 3 MASH trial, results from a completed Phase 2 alcohol-use-disorder study, and an ongoing Phase 2 study in alcohol-associated liver disease.
Generate the Altimmune report
Altimmune is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Altimmune and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Altimmune
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.